Conference Call with Sun Pharmaceutical Industries Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Sun Pharmaceutical Industries announced Q3FY25 results Gross sales at Rs 134,369 million, growth of 10.5%. India formulation sales at Rs 43,004 million, up 13.8%. US formulation sales at USD 474 million, down 0.7%. Global Specialty sales at USD 370 million, including USD 45 million milestone. Ex-milestones, up 17.5%. Global Specialty sales, ex-milestone, accounted for 21% of Q3FY25 sales. Emerging Markets formulation sales at USD 277 million, up 10.1%. Rest of World formulation sales at USD 259 million, up 21%. R&D; investments at Rs 8,450 million compared to Rs 8,245 million for Q3FY24. EBITDA at Rs 40,090 million (including other operating revenues), up 15.3%, with resulting EBITDA margin of 29.3%. Adjusted net profit (excluding the exceptional items) for Q3FY25 was Rs 32,196 million, up 24.1%. Reported net profit for Q3FY25 was Rs 29,034 million compared to Rs 25,238 million during Q3FY24. Dilip Shanghvi, Chairman & Managing Director, said: “Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales. Our market share gain in India has been driven by industry leading volume growth. Emerging Markets demonstrated strong performance in spite of currency challenges across geographies. All our businesses remain well positioned for future.” Result PDF